-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aflibercept in Optic Neuropathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aflibercept in Optic Neuropathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aflibercept in Optic Neuropathy Drug Details: Aflibercept (Eylea / Eylea HD) is...
-
Product Insights
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Drugs In Development, 2023
Global Markets Direct’s, ‘Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Drugs In Development, 2023’, provides an overview of the Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Optic Neuritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Optic Neuritis - Drugs In Development, 2023’, provides an overview of the Optic Neuritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Optic Neuritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Optic Neuropathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Optic Neuropathy - Drugs In Development, 2023’, provides an overview of the Optic Neuropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Optic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Optic Nerve Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Optic Nerve Injury - Drugs In Development, 2023’, provides an overview of the Optic Nerve Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Optic Nerve Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewDynamin Like 120 kDa Protein Mitochondrial – Drugs In Development, 2024
The Dynamin Like 120 kDa Protein Mitochondrial pipeline drugs market research report outlays comprehensive information on the Dynamin Like 120 kDa Protein Mitochondrial targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Ophthalmology which include indications of Ophthalmology, and Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy). It also reviews key players involved in Dynamin Like 120 kDa Protein...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AXER-204 in Chronic Spinal Cord Injury
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AXER-204 in Chronic Spinal Cord Injury report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AXER-204 in Chronic Spinal Cord Injury Drug Details: AXER-204...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ACT-001 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ACT-001 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ACT-001 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: ACT-001...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ST-266 in Necrotizing Enterocolitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ST-266 in Necrotizing Enterocolitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ST-266 in Necrotizing Enterocolitis Drug Details: ST-266 is under development for...
-
Product Insights
NewBeta Nerve Growth Factor – Drugs In Development, 2024
The Beta Nerve Growth Factor pipeline drugs market research report outlays comprehensive information on the Beta Nerve Growth Factor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Ophthalmology, Cardiovascular, and Hematological Disorders which include indications of Cancer Pain, Pain, Glaucoma, Optic Nerve Injury, Myocardial Infarction, Cardiac Arrest, and Sickle Cell Disease. It also reviews...